Contact

Gentle Clearing 56 Home About Services Evidence Overview Safety & Risks Comparative Context Contact Independent context / September 2026 Ibogaine Addiction Research: The Evidence Base A careful look at promise, uncertainty, safety, and the distance between observational signals and established addiction treatment. Evidence should be separated from appeal. The central distinction Ibogaine is a high-risk, investigational addiction treatment with promising but low-certainty efficacy signals. It is not an established alternative to methadone or buprenorphine. Interest in ibogaine has grown because some people describe a rapid interruption of opioid withdrawal, drug craving, and compulsive use after a single session. That appeal matters in the context of global addiction and overdose risk, but it does not settle efficacy and safety. Existing research findings are mostly observational, often small, and shaped by variable treatment protocols. This page distinguishes what is known from what is inferred. It considers clinical trials, patient outcomes, safety reports, neurobiological mechanisms, and the practical question of whether a psychedelic drug can be studied without overstating its therapeutic potential. For a foundation on drug scheduling, the U.S. controlled-substance scheduling framework explains why research access can be constrained. Origin / scope What the compound is—and is not Ibogaine is an indole alkaloid derived from the root bark of the Tabernanthe iboga plant, native to Central West Africa. Traditionally, indigenous Bwiti cultures use iboga in ritualistic ceremonies for spiritual experiences and healing purposes. That traditional use should not be collapsed into commercial detox programs or clinical settings, which differ in material, supervision, intent, and accountability. As a psychoactive substance, ibogaine can induce profound introspective states and altered perception. Its psychoactive properties are part of the reason it attracts interest, but

A clear line for thoughtful feedback.